Nexstim receives an NBS system order from the hospital
Press release, Helsinki, December 9th 2022 at 9 I AM (UN)
Nexstim receives an NBS System Order from hospital in Poland
Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or the “Company”) has received an NBS 5 system order from a Polish hospital.
This is Nexstim’s first sale to Poland. The system is used to plan neurosurgery for patients diagnosed with a brain tumor or other disorder. The Nexstim NBS system is the only FDA-approved and CE-marked navigated TMS system for preoperative mapping of the brain’s motor and speech cortex.
Nexstim CEO Mikko Karvinen commented: “We are proud of successful work stren.gthen ours presence in the European market. Reporting this sale to Poland is aget a step ahead us in to new markets and expand our user community. Our sales this year are represented a good new customer acquisition balancep and maintaining existing customer relationships – Nexstim’s world-leading technology is now available to more patients than ever before.”
More information is available on the website www.nexstim.comor by contacting:
Mikko KarvinenMANAGING DIRECTOR
+358 50 326 4101
[email protected]
About Nexstim Plc
Nexstim is a Finnish, globally operating, growth-oriented medical technology company. Our mission is to enable individual and effective diagnostics and treatment for challenging brain diseases and disorders.
Nexstim has developed the world’s leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) and highly advanced 3D navigation that provides precise and personalized targeting of TMS to a specific brain area.
Nexstim’s diagnostics business focuses on the commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA-approved and CE-marked navigated TMS system for pre-surgical mapping of the brain’s speech and motor cortex.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA approved for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE-marked for the treatment of severe depression and chronic neuropathic pain.
Nexstim’s shares are listed on Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
More information can be found at www.nexstim.com
